CA-QUANTA-CLOUD-TECH
Quanta Cloud Technology (QCT), a leading data center hardware solution provider, today announced details around its participation at the Big 5G Event 2021 , being held onsite as well as virtually from August 30 – September 3, at the Colorado Convention Center, Denver. QCT will showcase 5G demos and solutions developed alongside ecosystem partners (Intel, Red Hat, Robin.io, Wind River, DZS) at Booth #900a for both public and private networks and share their latest insights at the event.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210826005348/en/
QCT 5G Demos, Solutions, and Partner Highlights at the Big 5G Event:
QCT 5G solutions span data center and edge, to on-premise, with two major product lines, IronInfra and OmniPOD , to address infrastructure modernization and digital transformation needs.
-
IronInfra Product Line
: QCT provides IronCloud and IronEdge solutions for telecom infrastructures.
-
IronCloud - Network Function Virtualization Infrastructure (NFVI) solutions for telecom operators. QCT IronCloud provides cloud native infrastructures for mobile network operators running 5G core, vRAN, CNFs, and CDN use cases through its ecosystem partnerships.
-
IronEdge - QCT’s edge solutions that have been approved by the Telecom Infra Project for building and supporting Open RAN in different scenarios, including Centralized RAN, Distributed RAN and MEC use cases.
-
-
OmniPOD Product Line
: End-to-end enterprise 5G network solutions that help achieve the realization of dynamic 5G applications and services.
-
OmniCore : QCT’s cloud-native, virtualized 5G core network solution that features high-availability designs to meet reliability demands and allows for the optimization of network functions.
-
OmniRAN : QCT’s 5G RAN solution consisting of BBU, FHGW, and RRU with flexible system configurations to fulfill diverse coverage and capacity needs.
-
OmniView : QCT’s Operations Administration and Management (OAM) system to manage and monitor OmniCore and OmniRAN.
-
-
Ecosystem Partner Highlights
: Developments alongside the following partners will be on-hand.
-
Intel/Red Hat : QCT builds an Open RAN CU/DU with Red Hat OpenShift, Intel FlexRAN and OpenNESS operator. It achieves automation of installation and configuration and allows easy resource management and monitoring for operators.
-
Robin.io : QCT and Robin.io developed an open and extensible cloud-native automation platform for deployment and lifecycle management of the entire 5G stack, both VNF and CNF with industry leading TCO.
-
Wind River : As a first wave partner to the Wind River Studio Hardware Ready Program, QCT completed self-validation with data center and edge servers which benefit service providers in quickly reducing OPEX while accelerating the introduction of new high-value services.
-
DZS : The QCT and DZS Converged Edge Cloud Blueprints provide simple, easy-to-deploy, jointly validated reference configurations of hardware and software for 5G network services and deployments across the Core, RAN, and Edge Access domains.
-
QCT experts will be available at Booth #900a to share their 5G journey and deployments for multiple customer POCs across industry verticals such as manufacturing, agriculture, and entertainment. Learn more at: https://go.qct.io/telco/
About Quanta Cloud Technology (QCT)
Quanta Cloud Technology (QCT) is a global data center solution provider that combines the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center design and operational challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.
Product lines include hyperconverged and software-defined data center solutions as well as servers, storage, switches and integrated racks with an ecosystem of hardware components and software partners. QCT designs, manufactures, integrates and services its offerings via its own global network. The parent of QCT is Quanta Computer, Inc., a Fortune Global 500 corporation. www.QCT.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20210826005348/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
